The VRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the VRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The VRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View VRX Detailed Price Forecast - CNN Money||View VRX Detailed Summary - Google Finance|
|View VRX Detailed Summary - Yahoo! Finance||View VRX Stock Research & Analysis - Zacks.com|
|View VRX Trends & Analysis - Trade-Ideas||View VRX Major Holders - Barrons|
|View VRX Call Transcripts - NASDAQ||View VRX Breaking News & Analysis - Seeking Alpha|
|View VRX Annual Report - CompanySpotlight.com||View VRX OTC Short Report - OTCShortReport.com|
|View VRX Fundamentals - TradeKing||View VRX SEC Filings - Bar Chart|
|View Historical Prices for VRX - The WSJ||View Performance/Total Return for VRX - Morningstar|
|View the Analyst Estimates for VRX - MarketWatch||View the Earnings History for VRX - CNBC|
|View the VRX Earnings - StockMarketWatch||View VRX Buy or Sell Recommendations - MacroAxis|
|View the VRX Bullish Patterns - American Bulls||View VRX Short Pain Metrics - ShortPainBot.com|
|View VRX Stock Mentions - StockTwits||View VRX Stock Mentions - PennyStockTweets|
|View VRX Stock Mentions - Twitter||View VRX Investment Forum News - Investor Hub|
|View VRX Stock Mentions - Yahoo! Message Board||View VRX Stock Mentions - Seeking Alpha|
|View Insider Transactions for VRX - SECform4.com||View Insider Transactions for VRX - Insider Cow|
|View VRX Major Holdings Summary - CNBC||View Insider Disclosure for VRX - OTC Markets|
|View Insider Transactions for VRX - Yahoo! Finance||View Institutional Holdings for VRX - NASDAQ|
|View VRX Stock Insight & Charts - FinViz.com||View VRX Investment Charts - StockCharts.com|
|View VRX Stock Overview & Charts - BarChart||View VRX User Generated Charts - Trading View|
Bausch + Lomb Receives 510(K) Clearance From FDA For Bausch + Lomb Ultra® Multifocal For Astigmatism Contact Lenses
Posted on Wednesday December 05, 2018
BRIDGEWATER, N.J., Dec. 5, 2018 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Bausch + Lomb ULTRA® Multifocal for Astigmatism contact lenses, the first multifocal toric lens to be available as a standard offering in the eye care professional's fit set. "Eye care professionals have routinely stressed the need to have a readily available contact lens that addresses both presbyopia and astigmatism, underscoring the critical vision needs of this growing patient population," said Joe Gordon, U.S. president, Bausch + Lomb.
VRX Escrow Corp. -- Moody's upgrades Bausch Health's CFR to B2 from B3; stable outlook
Posted on Friday November 09, 2018
Moody's Investors Service ("Moody's") upgraded the ratings of Bausch Health Companies Inc. ("Bausch Health") including the Corporate Family Rating to B2 from B3, the Probability of Default Rating to B2-PD from B3-PD, the senior secured rating to Ba2 from Ba3 and the senior unsecured rating to B3 from Caa1. "The upgrade reflects continued progress in Bausch Health's turnaround including organic growth in major business lines, resolution of the Xifaxan patent challenge, and Moody's expectation for continued debt reduction," stated Michael Levesque, Moody's Senior Vice President.
Bausch Health Launches ALTRENO™ (tretinoin) Lotion, 0.05% In The United States
Posted on Tuesday October 30, 2018
LAVAL, Quebec, Oct. 30, 2018 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the U.S. launch of ALTRENOTM (tretinoin) Lotion, 0.05% for the topical treatment of acne vulgaris in patients 9 years of age and older. ALTRENO Lotion is the first and only tretinoin available in a lotion for acne.
LAVAL, Quebec, Oct. 11, 2018 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced that the Journal of Drugs in Dermatology has published results of two identical Phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel group studies examining the efficacy and safety of ALTRENOTM (tretinoin) Lotion, 0.05%, the first formulation of tretinoin, a retinoid, in a lotion indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.1 The U.S. Food and Drug Administration approved the New Drug Application for ALTRENO Lotion on Aug. 24, 2018. In the studies, ALTRENO Lotion was shown to have significantly greater efficacy compared to vehicle in achieving treatment success, which was defined as at least a two-grade improvement from baseline in a global severity by Evaluator Global Severity Score (EGSS) and 'clear' or 'almost clear' skin.